 ContraFect Corporation CFRX, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research has been invited to discuss the potential role of DLAs to combat high consequence biodefense and biologic threats at 2020 American Society of Microbiology ASM Biothreats, being held January 28 30, 2020 at the Hyatt Regency Crystal City in Arlington, Virginia. Dr. Cassino will also discuss the potential role of the Companys lead product candidate exebacase, currently being studied in a pivotal Phase 3 trial, in addressing the downstream threat of hospital-acquired MRSA bacteremia for a potential bio-threat exposure with mass casualty events. 